Pharmaceuticals News

ORION OYJ        PÖRSSITIEDOTE – SISÄPIIRITIETO         10.8.2026 KLO 14.05         Orionin lisenssikumppani Tenax Therapeuticsin Faasi 3 LEVEL-tutkimus oraalisella levosimendaanilla sydämen...

EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q...

Curium acquires Abscint, adding the investigational HER2-targeting PET tracer ABS-011 and strengthening its oncology radiodiagnostic portfolio.

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with...

ELTON, United Kingdom, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Scottish craft brewer BrewDog, by Tilray Brands, Inc., today launched "Park IPA," a new campaign designed to make Punk IPA® synonymous with...

SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of...

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical...

Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026Self-administration pharmacokinetic (PK) results were comparable to...

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter   Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately...

NEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT...